A gene expression profile indicative of early stage HER2 targeted therapy response

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  O'Neill, Fiona ^a   Madden, Stephen F ^a   Clynes, Martin ^a   Crown, John ^a   Doolan, Padraig ^a   Aherne, Sinéad T ^a   O'Connor, Robert ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Breast cancer; HER2 predictive markers; Targeted therapies

Indexed keywords

AFATINIB; CAPECITABINE; CCND1 PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIRUBICIN; GEFITINIB; LAPATINIB; MDAMB453 PROTEIN; NERATINIB; NR3C1 PROTEIN; RB1CC1 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 84879496729     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-69     Document Type: Article

References (32)

1. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
2. O'Brien NA, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9(6):1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
3. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182. 10.1126/science.3798106, 3798106.
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3(4):237-252.
5. Geyer CE, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743. 10.1056/NEJMoa064320, 17192538.
6. Burris HA, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23(23):5305-5313. 10.1200/JCO.2005.16.584, 15955900.
7. Cameron D, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010, 15(9):924-934. 10.1634/theoncologist.2009-0181, 3228041, 20736298.
8. Guiu S, et al. Predictive factors of response in HER2-positive breast cancer treated by neoadjuvant therapy. J Oncol 2013, 2013:854121. 3657410, 23737784.
9. Berns K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402. 10.1016/j.ccr.2007.08.030, 17936563.
10. Konecny GE, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66(3):1630-1639. 10.1158/0008-5472.CAN-05-1182, 16452222.
11. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711. 10.1038/onc.2008.109, 2748240, 18408761.
12. Khelwatty SA, et al. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 2011, 39(2):483-491.
13. Yap TA, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28(25):3965-3972. 10.1200/JCO.2009.26.7278, 20679611.
14. Wong KK, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15(7):2552-2558. 10.1158/1078-0432.CCR-08-1978, 19318484.
15. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett 2005, 227(1):9-23. 10.1016/j.canlet.2004.11.015, 16051028.
16. Tsou HR, et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 2005, 48(4):1107-1131. 10.1021/jm040159c, 15715478.
17. O'Neill F, et al. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. Mol Cancer 2012, 11:41. 10.1186/1476-4598-11-41, 3439312, 22709873.
18. Jeffery IB, et al. Integrating transcription factor binding site information with gene expression datasets. Bioinformatics 2007, 23(3):298-305. 10.1093/bioinformatics/btl597, 17127681.
19. Doledec SC. D, Co-Inertia Analysis:an alternative method for studying species- environment relationships. Freshwater Biology 1994, 31:277-294.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
21. Martin A, Clynes M. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 1993, 11(1):49-58. 10.1007/BF00749057, 7763636.
22. Das J, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006, 49(23):6819-6832. 10.1021/jm060727j, 17154512.
23. Park JH, et al. Tumor burden is predictive of survival in patients with Non-small-cell lung cancer and with activating epidermal growth factor receptor mutations Who receive gefitinib. Clin Lung Cancer 2013, 14(4):383-389. 10.1016/j.cllc.2012.10.007, 23313171.
24. Subik K, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 2010, 4:35-41.
25. Xia W, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21(41):6255-6263. 10.1038/sj.onc.1205794, 12214266.
26. Corkery B, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009, 20(5):862-867. 10.1093/annonc/mdn710, 19150933.
27. Krol J, et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 2007, 6(12 Pt 1):3169-3179.
28. McGovern UB, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 2009, 8(3):582-591. 10.1158/1535-7163.MCT-08-0805, 19276163.
29. Wilson MS, et al. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 2011, 12(9):1256-1266. 10.2174/138945011796150244, 21443467.
30. Grovdal LM, et al. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 2012, 24(1):296-301. 10.1016/j.cellsig.2011.09.012, 21951604.
31. Sun KK, et al. Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy. Oncol Lett 2013, 5(1):373-377. 3525465, 23255952.
32. D'Alessio A, et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010, 123(2):387-396. 10.1007/s10549-009-0649-x, 19946741.